[ A21-110] Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Last updated 03.03.2022
Project no.:
A21-110
Commission:
Commission awarded on 15.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adult patients with moderate to severe plaque psoriasis
- Patients who are not candidates for conventional treatment in the framework of an initial systemic therapy: hint of minor added benefit.
- Patients who have had an inadequate response or who have been intolerant to systemic therapy: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-12-15.
| Project no. | Title | Status |
|---|---|---|
| A24-64 | Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-07 | Bimekizumab (plaque psoriasis) - Addendum to Commission A21-110 | Commission completed |
| A23-61 | Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-62 | Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-60 | Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-03-03 A G-BA decision was published.